Xilio Therapeutics (XLO) Free Cash Flow (2020 - 2026)

Xilio Therapeutics (XLO) has 7 years of Free Cash Flow data on file, last reported at -$22.9 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 179.83% year-over-year to -$22.9 million; the trailing twelve-month figure through Mar 2026 stood at -$57.0 million (down 374.2% YoY), and the FY2025 full-year result was -$5.4 million, up 70.48% from the prior year.
• Free Cash Flow declined to -$22.9 million in Q1 2026, from -$2.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $28.7 million in Q1 2025 to a low of -$25.4 million in Q1 2023.
• A 5-year average of -$11.3 million and a median of -$14.6 million in 2025 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow surged 372.6% in 2025 and tumbled 179.83% in 2026, its largest moves.
• Tracing XLO's Free Cash Flow over 5 years: stood at -$16.9 million in 2022, then climbed by 20.48% to -$13.4 million in 2023, then dropped by 5.48% to -$14.2 million in 2024, then soared by 85.75% to -$2.0 million in 2025, then sank by 1034.74% to -$22.9 million in 2026.
• Business Quant data shows XLO's Free Cash Flow at -$22.9 million in Q1 2026, -$2.0 million in Q4 2025, and -$17.5 million in Q3 2025.